Equities analysts expect Sophiris Bio Inc (NASDAQ:SPHS) to report earnings of ($0.14) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Sophiris Bio’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.08). Sophiris Bio reported earnings of ($0.11) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 27.3%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 8th.
On average, analysts expect that Sophiris Bio will report full year earnings of ($0.60) per share for the current year, with EPS estimates ranging from ($0.69) to ($0.48). For the next year, analysts expect that the business will post earnings of ($0.59) per share, with EPS estimates ranging from ($0.65) to ($0.54). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Sophiris Bio.
Sophiris Bio (NASDAQ:SPHS) last issued its earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.05).
In other news, insider Randall E. Woods bought 10,000 shares of the stock in a transaction that occurred on Wednesday, September 19th. The shares were acquired at an average cost of $2.63 per share, for a total transaction of $26,300.00. Following the completion of the acquisition, the insider now owns 10,000 shares in the company, valued at $26,300. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 5.50% of the stock is currently owned by insiders.
A hedge fund recently raised its stake in Sophiris Bio stock. Northern Trust Corp raised its stake in Sophiris Bio Inc (NASDAQ:SPHS) by 293.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 80,600 shares of the biopharmaceutical company’s stock after purchasing an additional 60,092 shares during the period. Northern Trust Corp owned 0.27% of Sophiris Bio worth $226,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.59% of the company’s stock.
Shares of SPHS opened at $2.15 on Thursday. Sophiris Bio has a 1-year low of $1.80 and a 1-year high of $4.05. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 1.30.
About Sophiris Bio
Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.
Featured Article: Does the discount rate affect the economy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.